The DOI matches its Crossref record; 108 of the 108 references it cites were found in a registry or an index.
Hepatocellular Carcinoma: Consensus Recommendations of the National Cancer Institute Clinical Trials Planning Meeting
Open accessAbstract
Hepatocelluar carcinoma (HCC) is the most common primary malignancy of the liver in adults and the third most common cause of cancer death worldwide. The incidence of HCC in the United States is rising steadily because of the prevalence of hepatitis C viral infection and other causes of hepatic cirrhosis. The majority of patients have underlying hepatic dysfunction, which complicates patient management and the search for safe and effective therapies. The Clinical Trials Planning Meeting (CTPM) in HCC was convened by the National Cancer Institute's Gastrointestinal Cancer Steering Committee to identify the key knowledge gaps in HCC and define clinical research priorities. The CTPM structured its review according to current evidence-based treatment modalities in HCC and prioritized the recommendations on the basis of the patient populations representing the greatest unmet medical need.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Self-citationSorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Edge, S. B., & Compton, C. C. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-0985-4 · Cited by 9,029
Mazzaferro, V., Regalia, E., Doci, R., Andreola, S., Pulvirenti, A., Bozzetti, F., Montalto, F., Ammatuna, M., Morabito, A., & Gennari, L. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603143341104 · Cited by 7,186
Management of Hepatocellular Carcinoma *
Bruix, J., & Sherman, M. (2005) · Hepatology · doi:10.1002/hep.20933 · Cited by 5,857
Cheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification
Llovet, J., Brú, C., & Bruix, J. (1999) · Seminars in Liver Disease · doi:10.1055/s-2007-1007122 · Cited by 3,805
Llovet, J. M., Real, M. I., Montaña, X., Planas, R., Coll, S., Aponte, J., Ayuso, C., Sala, M., Muchart, J., Solà, R., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08649-x · Cited by 3,494
Rising Incidence of Hepatocellular Carcinoma in the United States
El-Serag, H. B., & Mason, A. C. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903113401001 · Cited by 2,853
Cited by
Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
Jacobson, I. M., McHutchison, J. G., Dusheiko, G., Di Bisceglie, A. M., Reddy, K. R., Bzowej, N. H., Marcellin, P., Muir, A. J., Ferenci, P., Flisiak, R., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1012912 · Cited by 2,398
Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study
Park, J., Chen, M., Colombo, M., Roberts, L. R., Schwartz, M., Chen, P., Kudo, M., Johnson, P., Wagner, S., Orsini, L. S., et al. (2015) · Liver International · doi:10.1111/liv.12818 · Cited by 1,245
Lencioni, R., de Baere, T., Soulen, M. C., Rilling, W. S., & Geschwind, J. H. (2016) · Hepatology · doi:10.1002/hep.28453 · Cited by 732
Salem, R., Lewandowski, R. J., Kulik, L., Wang, E., Riaz, A., Ryu, R. K., Sato, K. T., Gupta, R., Nikolaidis, P., Miller, F. H., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.10.049 · Cited by 650
Zhu, A. X., Rosmorduc, O., Evans, T. R. J., Ross, P. J., Santoro, A., Carrilho, F. J., Bruix, J., Qin, S., Thuluvath, P. J., Llovet, J. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.7746 · Cited by 576
Kudo, M., Imanaka, K., Chida, N., Nakachi, K., Tak, W.-Y., Takayama, T., Yoon, J.-H., Hori, T., Kumada, H., Hayashi, N., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.05.007 · Cited by 570
Kokudo, T., Hasegawa, K., Matsuyama, Y., Takayama, T., Izumi, N., Kadoya, M., Kudo, M., Ku, Y., Sakamoto, M., Nakashima, O., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.05.044 · Cited by 491
Yao, F. Y., Mehta, N., Flemming, J., Dodge, J., Hameed, B., Fix, O., Hirose, R., Fidelman, N., Kerlan, R. K., & Roberts, J. P. (2015) · Hepatology · doi:10.1002/hep.27752 · Cited by 485
Self-citationYuan, S.-X., Yang, F., Yang, Y., Tao, Q.-F., Zhang, J., Huang, G., Yang, Y., Wang, R.-Y., Yang, S., Huo, X.-S., et al. (2012) · Hepatology · doi:10.1002/hep.25895 · Cited by 374
Radioembolization for hepatocellular carcinoma
Sangro, B., Iñarrairaegui, M., & Bilbao, J. I. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.07.012 · Cited by 315
Landon, C. D. (2011) · The Open Nanomedicine Journal · doi:10.2174/1875933501103010038 · Cited by 281
Liu, Y., Liu, Y., Yan, X., Xu, Y., Luo, F., Ye, J., Yan, H., Yang, X., Huang, X., Zhang, J., et al. (2014) · Tumor Biology · doi:10.1007/s13277-014-2056-0 · Cited by 37
“Despite scientific advances, the prognosis for HCC patients remains poor, due to intra- and extrahepatic metastases and post-surgical recurrence [24].”
Background
Metadata
- Authors
- Thomas, M. B., Jaffe, D., Choti, M. M., Belghiti, J., Curley, S., Fong, Y., Gores, G., Kerlan, R., Merle, P., O'Neil, B., Poon, R., Schwartz, L., Tepper, J., Yao, F., Haller, D., Mooney, M., & Venook, A.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-09-01
- Volume
- 28
- Issue
- 25
- Pages
- 3994-4005
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2103362199
- Cited by
- 394
- References
- 108
- FWCI
- 18.44
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.